Morales Mallory 4

What Happened

Morales Mallory, SVP Finance and CAO of Immuneering Corp (IMRX), was granted a derivative award covering 140,000 shares on February 3, 2026. The Form 4 reports acquisition of 140,000 derivative securities at an exercise/acquisition price of $0.00 (no cash paid at grant). This was a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date and price: 2026-02-03; 140,000 derivative shares at $0.00 (reported as an award/grant, code A).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing February 1, 2026, and will be fully vested and exercisable on January 1, 2030 (Footnote F1).
• Filing timeliness: Form filed 2026-02-05 (appears within the typical 2-business-day Form 4 reporting window).

Context

This was a grant of a derivative award (an option) as part of compensation — no immediate cash was exchanged and no shares were sold. The award’s future value depends on Immuneering’s stock price and the holder’s decision to exercise and/or sell in the future; such grants are common executive compensation and do not by themselves indicate a buy or sell signal.